How Long Does It Take for GLP-1 to Work? A Realistic First-Month Timeline

GLP-1 receptor agonists begin working within hours of the first dose — appetite suppression, reduced hunger, and earlier fullness during meals are common within the first one to two weeks. However, because therapy starts at a low dose that is gradually increased (titrated) over four to eight weeks to limit nausea, measurable weight loss in the first month is usually modest: roughly 2 to 5 pounds (about 1 to 2% of body weight). The more dramatic, visible weight loss begins in months two and three as the dose reaches its target level. In the STEP 1 trial of weekly semaglutide for obesity, weight reduction accumulated steadily across the first 12 to 16 weeks before plateauing later in treatment (Wilding et al., NEJM 2021).

Within the first week, a GLP-1 receptor agonist mimics the natural GLP-1 gut hormone to slow gastric emptying (food leaves the stomach more slowly), increase satiety signals to the brain, and reduce fasting and post-meal glucose in people with type 2 diabetes. Patients most often notice smaller portion sizes feeling sufficient, fewer cravings, and less "food noise." The starting dose is intentionally low (for example, 0.25 mg weekly for semaglutide) specifically so the gastrointestinal system can adapt; this is why week-one weight change is usually small.

During the first four weeks of semaglutide, most patients lose approximately 2 to 5 pounds, though individual results vary widely based on starting weight, dose, diet, and adherence. This early loss reflects the low starting dose and the titration schedule. In the STEP 1 trial, adults on once-weekly semaglutide lost an average of about 15% of body weight over 68 weeks, but the weekly rate of loss accelerated after the dose was escalated past the initial 0.25 mg and 0.5 mg steps (Wilding et al., NEJM 2021). A gradual titration schedule improves adherence and reduces side effects (Eldor et al., Diabetes Care 2025).

The dose-escalation (titration) schedule exists almost entirely to manage gastrointestinal side effects — nausea, vomiting, diarrhea, and bloating — which are most frequent when the dose jumps suddenly. Starting low and increasing every four weeks lets the body adapt. A 2025 randomized study found that a slower, flexible 16-week titration of semaglutide produced better adherence and fewer adverse events than the standard 8-week schedule (Eldor et al., Diabetes Care 2025). This is also why the first month often shows limited weight loss: the effective therapeutic dose has not yet been reached.

Tirzepatide (Mounjaro, Zepbound) tends to produce weight loss at a somewhat faster rate and to a greater total magnitude than semaglutide. In the SURMOUNT-1 trial, adults on tirzepatide lost up to 22.5% of body weight over 72 weeks (Jastreboff et al., NEJM 2022), and a 2025 head-to-head trial directly confirmed tirzepatide achieved greater weight reduction than semaglutide in adults with obesity (Aronne et al., NEJM 2025). Both drugs still follow a titration schedule, so the difference in the very first month is relatively small; the separation becomes more apparent from the second month onward.

Not seeing scale movement in the first four weeks is common and does not mean the medication is failing. The most frequent reasons are the low starting dose during titration, fluid retention masking fat loss, dietary compensation, or simply normal biological variation. Signs the medication is biologically active even without weight change include reduced appetite, earlier fullness, fewer cravings, and smaller portions. Sustained, visible weight loss typically begins once the dose is escalated closer to the therapeutic target in weeks five through twelve. If you have concerns, contact your prescribing physician rather than self-adjusting the dose.